common.study.topics.clinical

Reprometabolic Syndrome Mediates Subfertility in Obesity

common.study.values.description

Reprometabolic Syndrome Mediates Subfertility in Obesity

Obesity plays an adverse role at every stage of conception and pregnancy and mounting evidence implicates relative hypogonadotropic hypogonadism, and reduced menstrual cycle hormone secretion as likely contributors to the subfertility phenotype and possible contributors to complications of pregnancy and the developmental origin of adult diseases such as diabetes and cardiovascular disease. This study will be the first comprehensive investigation to tie together the patterns of hyperinsulinemia, hyperlipidemia and inflammation, characteristic of obesity and obesity-caused relative hypogonadotropic hypogonadotropism and its potential adverse reproductive outcomes. The investigators findings will be used to inform a subsequent clinical intervention to optimize reproductive outcomes for obese women and their offspring.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Insulin

Drug - Intralipid

Drug - Dextrose

Drug - Heparin

Drug - GnRH

Procedure - Hyperinsulinemic Euglycemic Clamp

participant.views.study.view.additional

participant.views.study.view.scientific-title

Reprometabolic Syndrome Mediates Subfertility in Obesity

common.study.values.clinical-trial-id

NCT02653092

participant.views.study.view.id

QdJWye